Bhaskar Roy, MBBS, MHS
Associate Professor of NeurologyCards
About
Titles
Associate Professor of Neurology
Director of the Muscular Dystrophy Association adult care clinic, Neurology; Medical Director of the Electrodiagnostic Laboratory, Yale Medicine
Positions outside Yale
Co-Chair of the IBM scientific interest group from IMACS, IMACS, IMACS
Biography
Dr Bhaskar Roy is a specialist in neuromuscular disorders. His clinical areas of expertise includes muscular dystrophies, inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), autoimmune neuromuscular disorders, including inflammatory neuropathies. He did his neurology residency from the University of Connecticut and completed his fellowship from the Beth Israel Deaconess Medical Center, Harvard Medical School.
He is board certified in neurology (2016) and neuromuscular medicine (2018) by the American Board of Psychiatry and Neurology (ABPN) and in electrodiagnostic medicine (2018), and in Neuromuscular Ultrasound (2020) by the American Board of Electrodiagnostic Medicine (ABEM).
Appointments
Neurology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- MHS
- Yale University School of Medicine (2020)
- Neuromuscular Medicine Fellow
- Beth Israel Deaconess Medical Center (2017)
- Resident Physician
- University of Connecticut (2016)
- Post Doctoral Research Fellow
- Brigham and Women's Hospital, Harvard Medical School (2012)
- MBioMedSci
- Indian Institution of Technology, Masters in Medical Science and Technology (MMST) (2011)
- MBBS
- Nilratan Sircar Medical College and Hospital (2008)
Research
Publications
2024
546VP Deep immunoprofiling in inclusion body myositis and trajectory analysis
Roy B, DiStasio M, Hackbarth R, Bahrassa F, Joo D, Pham M, O'Connor K. 546VP Deep immunoprofiling in inclusion body myositis and trajectory analysis. Neuromuscular Disorders 2024, 43: 104441.137. DOI: 10.1016/j.nmd.2024.07.146.Peer-Reviewed Original ResearchCytotoxic T cellsInclusion body myositis patientsInclusion body myositisIdiopathic inflammatory myopathiesT cell repertoireT cellsB cell repertoireHealthy controlsB cellsExpression of cytotoxic markersIBM pathogenesisSpatial transcriptomic analysisAnalysis of peripheral blood mononuclear cellsPeripheral blood mononuclear cellsCD8 T cellsDifferentiation of cytotoxic T cellsT cell differentiation pathwayMemory B cellsBlood mononuclear cellsAbundant plasma cellsAsymmetric muscle weaknessInflammatory myopathiesCytotoxic markersTranscriptome analysis of muscle tissuesPlasma cellsSafety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
Allen J, Lin J, Basta I, Dysgaard T, Eggers C, Guptill J, Gwathmey K, Hewamadduma C, Hofman E, Hussain Y, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu M, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis R, van Doorn P, Grinzinger S, Wanschitz J, Seifert-Held T, Claeys K, Baets J, Remiche G, Bissay V, Dubuisson N, Delstanche S, Tarnev I, Genov K, Tsvetanov P, Milanov I, Zhao C, Bu B, Yu X, Li W, Jiang H, Da Y, Lu Z, Liang H, Guo F, Li Z, Zou Z, Hong D, Yang H, Guo J, Shi J, Tu J, He D, Wang Y, Ding J, Zhang Y, Zhao Y, Xu R, Yue Y, Guo A, Wang Y, Talab R, Harbo T, Sindrup S, De Seze J, Sacconi S, Péréon Y, Echaniz-Laguna A, Magy L, Nicolas G, Taithe F, Cassereau J, Debs R, Shakarishvili R, Tsiskaridze A, Mania M, Janelidze M, Janelidze T, Schroeter M, Skripuletz T, Lee D, Klehmet J, Hotter B, Hoffmann O, Baum P, Zschuentzsch J, Pitarokoili K, Stettner M, Bereczki D, Pánczél G, Abraham A, Dori A, Lampl Y, Manganelli F, Morino S, Padovani A, Siciliano G, Schenone A, Magri F, Mazzeo A, Giannini F, Sorbi S, Chiò A, Kuwahara M, Okuno T, Okamoto T, Kokubun N, Nishiyama K, Kaida K, Bokuda K, Katsuno M, Yabe I, Saji E, Yokota T, Hatanaka Y, Nakahara J, Sugimoto T, Tanaka F, Tomita S, Yamano Y, Hayashi T, Yamazaki H, Tokashiki T, Horiuchi K, Karelis G, Eftimov F, Banach M, Chyrchel-Paszkiewicz U, Kochanowicz J, Selmaj K, Zielinski T, Banaszkiewicz K, Mitrea D, Scutaru-Kadar A, Axelerad A, Stuchevskaya F, Boyko A, Khabirov F, Trushnikova T, Goncharova Z, Suponeva N, Dorogov N, Yakupov E, Raicevic R, Miletic Drakulic S, Cabrera Serrano M, Muñoz Blanco J, Guerrero Sola A, Aguera Morales E, Diaz Marin C, Juntas Morales R, Yeh J, Sung J, Huang H, Tsai N, Guo Y, Chao C, Ro L, Sengun I, Terzi M, Alpaydin Baslo S, Koç F, Necdet Karli H, Shulga O, Smolko D, Doroshenko O, Tomakh N, Kyrychenko A, Seliuk O, Kalbus O, Skrypchenko I, Novakovska O, Carod-Artal F, Rinaldi S, Brennan K, Ellis S, Carr A, Matthews E, Traub R, Mozaffar T, Elliott M, Bhavaraju-Sanka R, Nance C, Levine T, Lisak R, Pasnoor M, Pulley M, Roy B, Govindarajan R, Sahagian G, Khella S, Jacob D, Kushlaf H, Sivakumar K, Melamed I, Sharma K, Quick A, Ubogu E, Lacomis D, Isa A, Brannagan T, Chen S, Katz J, Feinberg M, Pavlakis P, Lange D, Gudesblatt M, Tandan R, Gable K, Rivner M, Barnes B, Luke D, Mahuwala Z, Macwan S, Kwon P, Scott J, Altamimi S, Sabharwal P. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology 2024, 23: 1013-1024. PMID: 39304241, DOI: 10.1016/s1474-4422(24)00309-0.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsChronic inflammatory demyelinating polyradiculoneuropathyRisk of relapseInflammatory demyelinating polyradiculoneuropathyStage BStage ADouble-blindModified intention-to-treat populationIntention-to-treat populationOpen-label phaseInflammatory Neuropathy CauseInteractive response technologyPhase 2 trialPlacebo-controlled trialEvidence of clinical improvementClinically meaningful deteriorationPeripheral nervous systemPartial responseSafety populationPlacebo groupPlacebo-controlledResidual neurological impairmentClinical improvementWeeks treatmentTreatment options154VP Usage of disease modifying therapies in spinal muscular atrophy and existing disparities: a population-based study from the MDA MOVR database
McLaren N, Joo D, Nowak R, Roy B. 154VP Usage of disease modifying therapies in spinal muscular atrophy and existing disparities: a population-based study from the MDA MOVR database. Neuromuscular Disorders 2024, 43: 104441.589. DOI: 10.1016/j.nmd.2024.07.598.Peer-Reviewed Original ResearchDisease modifying therapiesSpinal muscular atrophySurvival motor neuron 1Muscular Dystrophy AssociationModifying therapiesMuscular atrophyWhite Caucasian patientsSpinal muscular atrophy typesType 1 SMAType 2 SMALife saving therapyAlpha motor neuronsPopulation-based studyGroup of inherited neurodegenerative disordersCaucasian patientsZolgensmaNeuron 1Type 3 SMASpinal cordMuscle atrophyNusinersenPatientsTherapyMotor neuronsRisdiplamProteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003)
Roy B, Habiabadi F, O’Connor K, Nowak R, Kaminski H. Proteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205944.Peer-Reviewed Original ResearchTrial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004)
Roy B, Nowak R. Trial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205956.Peer-Reviewed Original ResearchLifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003)
Armengol V, Darras B, Abulaban A, Alshehri A, Barisic N, Ben-Omran T, Bernert G, Castiglioni C, Chien Y, Farrar M, Kandawasvika G, Khadilkar S, Mah J, Marini-Bettolo C, Osredkar D, Pfeffer G, Piazzon F, Castellano I, Quijano-Roy S, Saito K, Shin J, Vázquez-Costa J, Walter M, Wanigasinghe J, Xiong H, Griggs R, Roy B. Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206000.Peer-Reviewed Original ResearchPharmacological Interventions for Pain Management in Diabetic Peripheral Neuropathy: A Network Meta-analysis of Randomised Controlled Trials (P5-13.003)
Suresh V, Dey D, Jayan M, Shamim M, Gupta S, Ramana D, Dave T, Jena R, Muneer M, Dhakal B, Ghosh S, Verma A, Garg A, Muzammil M, Bardhan M, Malhotra H, Kumar N, Mallick H, Roy B. Pharmacological Interventions for Pain Management in Diabetic Peripheral Neuropathy: A Network Meta-analysis of Randomised Controlled Trials (P5-13.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206325.Peer-Reviewed Original ResearchPhenotypic spectrum of inclusion body myositis.
Roy B, Dimachkie M, Naddaf E. Phenotypic spectrum of inclusion body myositis. Clinical And Experimental Rheumatology 2024, 42: 445-453. PMID: 38436356, DOI: 10.55563/clinexprheumatol/fhrx3q.Peer-Reviewed Original ResearchConceptsInclusion body myositisAtypical presentationInitiation of disease-modifying therapyDeep finger flexorsQuality of lifeLoss of hand functionBenefits of early diagnosisInclusion body myositis patientsYears of disease onsetDebilitating muscle diseaseTime to diagnosisFoot dropAsymptomatic hyper-CKemiaFinger flexorsQuadriceps muscleImpaired ambulationHand functionDisease-modifying therapiesGeneral populationFacial diplegiaAxial weaknessClinical spectrumIsolated dysphagiaProximal weaknessHyper-CKemia
2023
Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.
Armengol V, Darras B, Abulaban A, Alshehri A, Barisic N, Ben-Omran T, Bernert G, Castiglioni C, Chien Y, Farrar M, Kandawasvika G, Khadilkar S, Mah J, Marini-Bettolo C, Osredkar D, Pfeffer G, Piazzon F, Pitarch Castellano I, Quijano-Roy S, Saito K, Shin J, Vázquez-Costa J, Walter M, Wanigasinghe J, Xiong H, Griggs R, Roy B. Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability. Neurology Clinical Practice 2023, 14: e200224. PMID: 38107546, PMCID: PMC10723640, DOI: 10.1212/cpj.0000000000200224.Peer-Reviewed Original ResearchSurveyed health care providersProvider survey responsesHealth care providersSpinal muscular atrophyEconomic burdenNewborn screeningBarriers to treatmentMitigate such inequalitiesCare providersClinical careQualitative studyTreated patientsOutcome measuresMotor strengthGenetic testingSpinal muscular atrophy type 1Muscular atrophyProvidersSurvey responsesTreatment of spinal muscular atrophyLife-saving treatmentMuscle weaknessProgressive muscle weaknessNormal lifeTreatment costsBiallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections
Jeffries L, Mis E, McWalter K, Donkervoort S, Brodsky N, Carpier J, Ji W, Ionita C, Roy B, Morrow J, Darbinyan A, Iyer K, Aul R, Banka S, Chao K, Cobbold L, Cohen S, Custodio H, Drummond-Borg M, Elmslie F, Finanger E, Hainline B, Helbig I, Hewson S, Hu Y, Jackson A, Josifova D, Konstantino M, Leach M, Mak B, McCormick D, McGee E, Nelson S, Nguyen J, Nugent K, Ortega L, Goodkin H, Roeder E, Roy S, Sapp K, Saade D, Sisodiya S, Stals K, Towner S, Wilson W, Disorders D, Borras S, Clark C, Dean J, Miedzybrodzka Z, Ross A, Tennant S, Dabir T, Donnelly D, Humphreys M, Magee A, McConnell V, McKee S, McNerlan S, Morrison P, Rea G, Stewart F, Cole T, Cooper N, Cooper-Charles L, Cox H, Islam L, Jarvis J, Keelagher R, Lim D, McMullan D, Morton J, Naik S, O’Driscoll M, Ong K, Osio D, Ragge N, Turton S, Vogt J, Williams D, Bodek S, Donaldson A, Hills A, Low K, Newbury-Ecob R, Norman A, Roberts E, Scurr I, Smithson S, Tooley M, Abbs S, Armstrong R, Dunn C, Holden S, Park S, Paterson J, Raymond L, Reid E, Sandford R, Simonic I, Tischkowitz M, Woods G, Bradley L, Comerford J, Green A, Lynch S, McQuaid S, Mullaney B, Berg J, Goudie D, Mavrak E, McLean J, McWilliam C, Reavey E, Azam T, Cleary E, Jackson A, Lam W, Lampe A, Moore D, Porteous M, Baple E, Baptista J, Brewer C, Castle B, Kivuva E, Owens M, Rankin J, Shaw-Smith C, Turner C, Turnpenny P, Tysoe C, Bradley T, Davidson R, Gardiner C, Joss S, Kinning E, Longman C, McGowan R, Murday V, Pilz D, Tobias E, Whiteford M, Williams N, Barnicoat A, Clement E, Faravelli F, Hurst J, Jenkins L, Jones W, Kumar V, Lees M, Loughlin S, Male A, Morrogh D, Rosser E, Scott R, Wilson L, Beleza A, Deshpande C, Flinter F, Holder M, Irving M, Izatt L, Josifova D, Mohammed S, Molenda A, Robert L, Roworth W, Ruddy D, Ryten M, Yau S, Bennett C, Blyth M, Campbell J, Coates A, Dobbie A, Hewitt S, Hobson E, Jackson E, Jewell R, Kraus A, Prescott K, Sheridan E, Thomson J, Bradshaw K, Dixit A, Eason J, Haines R, Harrison R, Mutch S, Sarkar A, Searle C, Shannon N, Sharif A, Suri M, Vasudevan P, Canham N, Ellis I, Greenhalgh L, Howard E, Stinton V, Swale A, Weber A, Banka S, Breen C, Briggs T, Burkitt-Wright E, Chandler K, Clayton-Smith J, Donnai D, Douzgou S, Gaunt L, Jones E, Kerr B, Langley C, Metcalfe K, Smith A, Wright R, Bourn D, Burn J, Fisher R, Hellens S, Henderson A, Montgomery T, Splitt M, Straub V, Wright M, Zwolinski S, Allen Z, Bernhard B, Brady A, Brooks C, Busby L, Clowes V, Ghali N, Holder S, Ibitoye R, Wakeling E, Blair E, Carmichael J, Cilliers D, Clasper S, Gibbons R, Kini U, Lester T, Nemeth A, Poulton J, Price S, Shears D, Stewart H, Wilkie A, Albaba S, Baker D, Balasubramanian M, Johnson D, Parker M, Quarrell O, Stewart A, Willoughby J, Crosby C, Elmslie F, Homfray T, Jin H, Lahiri N, Mansour S, Marks K, McEntagart M, Saggar A, Tatton-Brown K, Butler R, Clarke A, Corrin S, Fry A, Kamath A, McCann E, Mugalaasi H, Pottinger C, Procter A, Sampson J, Sansbury F, Varghese V, Baralle D, Callaway A, Cassidy E, Daniels S, Douglas A, Foulds N, Hunt D, Kharbanda M, Lachlan K, Mercer C, Side L, Temple I, Wellesley D, Consortium G, Ambrose J, Arumugam P, Baple E, Bleda M, Boardman-Pretty F, Boissiere J, Boustred C, Caulfield M, Chan G, Craig C, Daugherty L, de Burca A, Devereau A, Elgar G, Foulger R, Fowler T, FurióTarí P, Hackett J, Halai D, Hamblin A, Henderson S, Holman J, Hubbard T, Ibáñez K, Jackson R, Jones L, Kasperaviciute D, Kayikci M, Lahnstein L, Lawson K, Leigh S, Leong I, Lopez F, MaleadyCrowe F, Mason J, McDonagh E, Moutsianas L, Mueller M, Murugaesu N, Need A, Odhams C, Patch C, Perez-Gil D, Polychronopoulos D, Pullinger J, Rahim T, Rendon A, Riesgo-Ferreiro P, Rogers T, Ryten M, Savage K, Sawant K, Scott R, Siddiq A, Sieghart A, Smedley D, Smith K, Sosinsky A, Spooner W, Stevens H, Stuckey A, Sultana R, Thomas E, Thompson S, Tucci A, Walsh E, Watters S, Welland M, Williams E, Witkowska K, Network U, Acosta M, Adam M, Adams D, Agrawal P, Alejandro M, Alvey J, Amendola L, Andrews A, Ashley E, Azamian M, Bacino C, Bademci G, Baker E, Balasubramanyam A, Baldridge D, Bale J, Bamshad M, Barbouth D, Bayrak-Toydemir P, Beck A, Beggs A, Behrens E, Bejerano G, Bennet J, Berg-Rood B, Bernstein J, Berry G, Bican A, Bivona S, Blue E, Bohnsack J, Bonnenmann C, Bonner D, Botto L, Boyd B, Briere L, Brokamp E, Brown G, Burke E, Burrage L, Butte M, Byers P, Byrd W, Carey J, Carrasquillo O, Chang T, Chanprasert S, Chao H, Clark G, Coakley T, Cobban L, Cogan J, Coggins M, Cole F, Colley H, Cooper C, Craigen W, Crouse A, Cunningham M, D'Souza P, Dai H, Dasari S, Davids M, Dayal J, Deardorff M, Dell'Angelica E, Dhar S, Dipple K, Doherty D, Dorrani N, Douine E, Draper D, Duncan L, Earl D, Eckstein D, Emrick L, Eng C, Esteves C, Estwick T, Falk M, Fernandez L, Ferreira C, Fieg E, Findley L, Fisher P, Fogel B, Forghani I, Fresard L, Gahl W, Glass I, Godfrey R, Golden-Grant K, Goldman A, Goldstein D, Grajewski A, Groden C, Gropman A, Gutierrez I, Hahn S, Hamid R, Hanchard N, Hassey K, Hayes N, High F, Hing A, Hisama F, Holm I, Hom J, Horike-Pyne M, Huang A, Huang Y, Isasi R, Jamal F, Jarvik G, Jarvik J, Jayadev S, Johnston J, Karaviti L, Kelley E, Kennedy J, Kiley D, Kohane I, Kohler J, Krakow D, Krasnewich D, Kravets E, Korrick S, Koziura M, Krier J, Lalani S, Lam B, Lam C, Lanpher B, Lanza I, Lau C, LeBlanc K, Lee B, Lee H, Levitt R, Lewis R, Lincoln S, Liu P, Liu X, Longo N, Loo S, Loscalzo J, Maas R, Macnamara E, MacRae C, Maduro V, Majcherska M, Mak B, Malicdan M, Mamounas L, Manolio T, Mao R, Maravilla K, Markello T, Marom R, Marth G, Martin B, Martin M, Martínez-Agosto J, Marwaha S, McCauley J, McCormack C, McCray A, McGee E, Mefford H, Merritt J, Might M, Mirzaa G, Morava E, Moretti P, Morimoto M, Mulvihill J, Murdock D, Nakano-Okuno M, Nath A, Nelson S, Newman J, Nicholas S, Nickerson D, Nieves-Rodriguez S, Novacic D, Oglesbee D, Orengo J, Pace L, Pak S, Pallais J, Papp J, Parker N, Phillips J, Posey J, Potocki L, Pusey B, Quinlan A, Raskind W, Raja A, Rao D, Renteria G, Reuter C, Rives L, Robertson A, Rodan L, Rosenfeld J, Rosenwasser N, Ruzhnikov M, Sacco R, Sampson J, Samson S, Saporta M, Scott C, Schaechter J, Schedl T, Scott D, Sharma P, Shin J, Signer R, Sillari C, Silverman E, Sinsheimer J, Sisco K, Smith E, Smith K, Solem E, Solnica-Krezel L, Stoler J, Stong N, Sullivan J, Sun A, Sutton S, Sweetser D, Sybert V, Tabor H, Tamburro C, Tekin M, Telischi F, Thorson W, Tifft C, Toro C, Tran A, Tucker B, Urv T, Vanderver A, Velinder M, Viskochil D, Vogel T, Wahl C, Wallace S, Walley N, Walsh C, Walker M, Wambach J, Wan J, Wang L, Wangler M, Ward P, Wegner D, Wener M, Wenger T, Perry K, Westerfield M, Wheeler M, Whitlock J, Wolfe L, Woods J, Yamamoto S, Yang J, Yu G, Zastrow D, Zhao C, Zuchner S, Khokha M, Bönnemann C, Lucas C, Lakhani S. Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Genetics In Medicine 2023, 26: 101023. PMID: 37947183, PMCID: PMC10932913, DOI: 10.1016/j.gim.2023.101023.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsPatient's immune cellsBlood mononuclear cellsImmune cell subtypesEarly-onset epilepsyAffected individualsInduced seizuresCardiac dysrhythmiasRecurrent infectionsClinical syndromeFrequent infectionsMononuclear cellsPatient cohortImmune cellsMultisystem syndromeHealthy donorsMultisystem disorderCardiac arrhythmiasBiallelic variantsCell subtypesDevelopmental delayGene variantsProtein overexpressionRecessive variantsMissense variants
Clinical Trials
Current Trials
Efficacy and Safety of ABC008 in Inclusion Body Myositis
HIC ID2000034270RolePrincipal InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
HIC ID2000031341RoleSub InvestigatorPrimary Completion Date02/21/2024Recruiting ParticipantsGenderBothAge18+ yearsMyasthenia Gravis Inebilizumab Trial (MINT)
HIC ID2000029503RoleSub InvestigatorPrimary Completion Date06/30/2023Recruiting ParticipantsGenderBothAge18+ yearsRegistry of Patients With Generalized Myasthenia Gravis Who Have Ever Been Treated With C5 Inhibition Therapies
HIC ID2000026785REGRoleSub InvestigatorPrimary Completion Date12/31/2021Recruiting ParticipantsExploring the relationship between electrical impedance myography (EIM) parameters with magnetic resonance imaging, and quantitative ultrasound parameters in Inclusion Body Myositis
HIC ID2000029791RolePrincipal InvestigatorPrimary Completion Date01/31/2024Recruiting ParticipantsGenderBothAge45 years - 90 years
Clinical Care
Overview
Bhaskar Roy, MBBS, (a medical degree awarded in several countries outside of the U.S.), is a neurologist who specializes in neuromuscular disorders and has deep expertise in using electromyography (EMG), a medical test that measures electrical activity in a patient’s nerves and muscles, to diagnose diseases. Dr. Roy cares for patients with muscular dystrophies, inflammatory myopathies (myositis), neuropathy, and autoimmune neuromuscular disorders. He is interested in rare and complex neuromuscular disorders, including inclusion body myositis (IBM) and other hereditary muscle diseases.
“Neuromuscular disorders are complex,” Dr. Roy says. “The challenge of diagnosis is what drew my attention to this field. These patients are a unique group of people who really need help. Some of them have gone undiagnosed for a long time.” Specialized neuromuscular care can help ensure that therapy is given as early as possible when applicable, he adds.
In addition to EMG, Dr. Roy is also trained in using neuromuscular ultrasound. “This is a relatively newer mode of technology that allows a physician to see some of the nerves and muscle tissue.”
Neuromuscular medicine has advanced rapidly in recent years and new drugs are available for patients with diseases that were previously not treatable, Dr. Roy says. His research on biomarkers—which are measurable markers that indicate a status of disease or health in the body—could help neurologists better understand a patient’s response to a treatment. In his studies, Dr. Roy uses electrical impedance myography (EIM), a painless test that assesses muscle health in a noninvasive way.
Dr. Roy is an assistant professor of neurology at the Yale School of Medicine.
Clinical Specialties
Neuromuscular Medicine; Neurology
Fact Sheets
Neuropathy
Learn More on Yale MedicineMuscular Dystrophy
Learn More on Yale MedicinePeripheral Neuropathy
Learn More on Yale MedicineGuillain-Barré Syndrome
Learn More on Yale Medicine
Yale Medicine News
News
Get In Touch
Contacts
Email
Appointment Number
Clinical Inquiry Number
Clinic Fax Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.